Romiplostim
- Generic Name
- Romiplostim
- Brand Names
- Nplate
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 267639-76-9
- Unique Ingredient Identifier
- GN5XU2DXKV
- Background
Romiplostim is a thrombopoiesis stimulating dimer Fc-peptide fusion protein (peptibody) to increase platelet production through activation of the thrombopoietin receptor. The peptibody molecule has two identical single-chain subunits, each one is made up of 269 amino acid residues. Each subunit consists of an IgG1 Fc carrier domain that is covalently attache...
- Indication
Treatment of chronic immune thrombocytopenic purpura.
- Associated Conditions
- Chronic immune thrombocytopenia, Refractory immune thrombocytopenia
- Associated Therapies
- -
A Study of Romiplostim for the Treatment of Refractory Transfusion-dependent NSAA
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06535685
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Ropustin for Refractory Aplastic Anaemia After Radiotherapy - a Single-centre, Prospective, Open-label, Single-arm Study
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06516484
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06345495
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Romiplostim in Chemotherapy-Induced Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 30
- Registration Number
- NCT06201663
- Locations
- 🇪🇬
Ain Shams University Children's Hospital, Cairo, Egypt
Romiplostim in Combination With CsA vs. CsA in the Treatment of Newly Diagnosed NSAA
- Conditions
- Interventions
- First Posted Date
- 2023-08-24
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT06009497
- Locations
- 🇨🇳
Peking union medical college hospital, Beijing, China
Immune Thrombocytopenia Management in Adults
- Conditions
- Interventions
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Nahda University
- Target Recruit Count
- 467
- Registration Number
- NCT05861297
- Locations
- 🇪🇬
EL-Kasr elineiy, Cairo, Egypt
Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Amgen
- Registration Number
- NCT05323617
Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma
- Conditions
- Interventions
- Locations
- 🇪🇸
Hospital Universitario Ramon y Cajal, Madrid, Spain
🇪🇸Hospital Universitario 12 De Octubre, Madrid, Spain
🇨🇭UniversitaetsSpital, Zürich, Switzerland
A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT04671901
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities), Commack, New York, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT04673266
- Locations
- 🇺🇸
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York, United States
🇺🇸Memorial Sloan Kettering Basking Ridge (All Protocol Activites), Basking Ridge, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.